Vaccinex, Inc. – NASDAQ:VCNX
Vaccinex stock price today
Vaccinex stock price monthly change
Vaccinex stock price quarterly change
Vaccinex stock price yearly change
Vaccinex key metrics
Market Cap | 3.23M |
Enterprise value | 11.48M |
P/E | -0.91 |
EV/Sales | 41.76 |
EV/EBITDA | -0.38 |
Price/Sales | 63.23 |
Price/Book | 3.34 |
PEG ratio | -0.01 |
EPS | -46.69 |
Revenue | N/A |
EBITDA | -22.89M |
Income | -19.18M |
Revenue Q/Q | -81.09% |
Revenue Y/Y | -140.30% |
Profit margin | -10833.82% |
Oper. margin | -10873.09% |
Gross margin | 0% |
EBIT margin | -10873.09% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVaccinex stock price history
Vaccinex stock forecast
Vaccinex financial statements
| Jun 2023 | 0 | -7.06M | |
|---|---|---|---|
| Sep 2023 | 20K | -4.91M | -24560% |
| Dec 2023 | -386K | -3.31M | 859.33% |
| Mar 2024 | 104K | -3.89M | -3747.12% |
| 2025 | 142.7M | 119.76M | 83.93% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3085000 | 3.50M | 113.71% |
|---|---|---|---|
| Sep 2023 | 2558000 | 6.42M | 251.25% |
| Dec 2023 | 3631000 | 5.94M | 163.65% |
| Mar 2024 | 7367000 | 4.71M | 63.96% |
| Jun 2023 | -5.50M | 0 | 4.09M |
|---|---|---|---|
| Sep 2023 | -3.09M | -18K | 1.33M |
| Dec 2023 | -3.59M | 0 | 5M |
| Mar 2024 | -4.63M | 0 | 6.06M |
Vaccinex alternative data
| Aug 2023 | 38 |
|---|---|
| Sep 2023 | 38 |
| Oct 2023 | 38 |
| Nov 2023 | 38 |
| Dec 2023 | 38 |
| Jan 2024 | 38 |
| Feb 2024 | 38 |
| Mar 2024 | 38 |
| Apr 2024 | 38 |
| May 2024 | 37 |
| Jun 2024 | 37 |
| Jul 2024 | 37 |
Vaccinex other data
| Period | Buy | Sel |
|---|---|---|
| Oct 2023 | 7010000 | 0 |
| Dec 2023 | 0 | 4483 |
| Apr 2024 | 282 | 0 |
| May 2024 | 1818 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | FRIEDBERG ALBERT director, 10 percent owner: | Common Stock | 861 | $5.2 | $4,473 | ||
Purchase | FRIEDBERG ALBERT director, 10 percent owner: | Common Stock | 957 | $4.95 | $4,737 | ||
Purchase | FRIEDBERG ALBERT director, 10 percent owner: | Common Stock | 282 | $4.73 | $1,334 | ||
Sale | VAN STRYDONCK, GERALD E. director | Common Stock | 3,149 | $0.72 | $2,267 | ||
Sale | VAN STRYDONCK, GERALD E. director | Common Stock | 1,334 | $0.67 | $894 | ||
Purchase | ZAUDERER MAURICE director, 10 perc.. | Common Stock | 5,000 | $0.97 | $4,865 | ||
Purchase | ZAUDERER MAURICE director, 10 perc.. | Common Stock | 500,000 | $1 | $500,000 | ||
Purchase | ZAUDERER MAURICE director, 10 perc.. | Warrant (Right to Buy) | 500,000 | $1 | $500,000 | ||
Purchase | ZAUDERER MAURICE director, 10 perc.. | Common Stock | 5,000 | $0.93 | $4,650 | ||
Purchase | FRIEDBERG ALBERT director, 10 percent owner: | Common Stock | 3,000,000 | $1 | $3,000,000 |
| Patent |
|---|
Application Filling date: 31 Jan 2022 Issue date: 16 Jun 2022 |
Grant Filling date: 28 Apr 2017 Issue date: 15 Mar 2022 |
Application Filling date: 21 Jun 2021 Issue date: 30 Dec 2021 |
Application Filling date: 8 Jun 2021 Issue date: 16 Dec 2021 |
Application Filling date: 5 May 2021 Issue date: 11 Nov 2021 |
Application USE OF SEMAPHORIN-4D INHIBITORY MOLECULES WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASES Filling date: 29 Jun 2021 Issue date: 21 Oct 2021 |
Application Filling date: 6 Jan 2021 Issue date: 5 Aug 2021 |
Grant Utility: Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases Filling date: 23 Apr 2019 Issue date: 3 Aug 2021 |
Application TREATMENT OF CANCER WITH A SEMAPHORIN-4D ANTIBODY IN COMBINATION WITH AN EPIGENETIC MODULATING AGENT Filling date: 14 Mar 2018 Issue date: 17 Jun 2021 |
Application Filling date: 24 Sep 2020 Issue date: 25 Mar 2021 |
| Insider | Compensation |
|---|---|
| Dr. Maurice Zauderer Ph.D. (1946) Co-Founder, Chief Executive Officer, Pres & Director | $357,260 |
| Dr. Ernest S. Smith Ph.D. (1971) Senior Vice President of Research & Chief Scientific Officer | $249,710 |
Mr. Scott E. Royer C.F.A., M.B.A. (1974) Chief Financial Officer | $231,700 |
-
What's the price of Vaccinex stock today?
One share of Vaccinex stock can currently be purchased for approximately $0.6.
-
When is Vaccinex's next earnings date?
Unfortunately, Vaccinex's (VCNX) next earnings date is currently unknown.
-
Does Vaccinex pay dividends?
No, Vaccinex does not pay dividends.
-
How much money does Vaccinex make?
Vaccinex has a market capitalization of 3.23M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 470% to 570K US dollars.
-
What is Vaccinex's stock symbol?
Vaccinex, Inc. is traded on the NASDAQ under the ticker symbol "VCNX".
-
What is Vaccinex's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vaccinex?
Shares of Vaccinex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vaccinex's key executives?
Vaccinex's management team includes the following people:
- Dr. Maurice Zauderer Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 79, pay: $357,260)
- Dr. Ernest S. Smith Ph.D. Senior Vice President of Research & Chief Scientific Officer(age: 54, pay: $249,710)
- Mr. Scott E. Royer C.F.A., M.B.A. Chief Financial Officer(age: 51, pay: $231,700)
-
Is Vaccinex founder-led company?
Yes, Vaccinex is a company led by its founder Dr. Maurice Zauderer Ph.D..
-
How many employees does Vaccinex have?
As Jul 2024, Vaccinex employs 37 workers, which is 3% less then previous quarter.
-
When Vaccinex went public?
Vaccinex, Inc. is publicly traded company for more then 7 years since IPO on 9 Aug 2018.
-
What is Vaccinex's official website?
The official website for Vaccinex is vaccinex.com.
-
Where are Vaccinex's headquarters?
Vaccinex is headquartered at 1895 Mount Hope Avenue, Rochester, NY.
-
How can i contact Vaccinex?
Vaccinex's mailing address is 1895 Mount Hope Avenue, Rochester, NY and company can be reached via phone at +58 52712700.
Vaccinex company profile:
Vaccinex, Inc.
vaccinex.comNASDAQ
37
Biotechnology
Healthcare
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Rochester, NY 14620
CIK: 0001205922
ISIN: US9186403013
CUSIP: 918640103
